Public health

Sessions

Wednesday, 23 November

10:50

Addressing substance use and substance use disorders in humanitarian settings: the role of evidence-based prevention, treatment and care

10:50 to 12:20

Insights zone 4 (I4)

Structured session

Commonalities across addictions

10:50 to 12:20

Insights zone 2 (I2)

Oral presentation session

COVID-19 implications for services and responses

10:50 to 12:20

Central square 3 (C3)

Oral presentation session

Current and future challenges associated with emerging cannabis markets

10:50 to 12:20

Main stage

Structured session

Substance-induced psychosis: register-linkage research in Nordic countries

10:50 to 12:20

Knowledge market 2 (K2)

Structured session

13:20

Assessing the impact of laws and policies regulating illicit drugs on health and society: some insights

13:20 to 14:50

Knowledge market 4 (K4)

Structured session

Cultures of prevention: training the workforce

13:20 to 14:50

Main stage

Structured session

The future for Digital Addictions Services. An update from the DigitAS-DADE Project

13:20 to 14:50

Central square 2 (C2)

Structured session

15:00

Drug Early Warning Systems – the key to preparedness and response to new psychoactive substances

15:00 to 16:30

Central square 2 (C2)

Structured session

Estimating harm

15:00 to 16:30

Central square 3 (C3)

Oral presentation session

Estimating prevalence

15:00 to 16:30

Knowledge market 4 (K4)

Oral presentation session

Injecting-related infections and drug surveillance

15:00 to 16:30

Knowledge market 3 (K3)

Oral presentation session

Towards endemicity: A global perspective of the many variants of drug consumption rooms and service models in operation

15:00 to 16:30

Insights zone 3 (I3)

Structured session

16:50

Assessment of drug policies in light of Sustainable Development Goals and human rights

16:50 to 18:20

Knowledge market 1 (K1)

Structured session

Economic recessions, COVID-19, socio-determinants of drug use and its harms: deaths of despair?

16:50 to 18:20

Central square 4 (C4)

Workshop

EU4MD Treatment facility survey

16:50 to 18:20

Networking zone 2 (N2)

Oral presentation session

Improving the health of people who use drugs

16:50 to 18:20

Networking zone 4 (N4)

Short communication session

Why we need evidence-based approaches for the universal measurement of cannabis: rationale and implications for public health, treatment and research

16:50 to 18:20

Main stage

Structured session

18:30

Psychedelic-assisted treatment for substance use disorders – long overlooked or now overhyped?

18:30 to 19:30

Main stage

Big debate

Thursday, 24 November

09:00

Contemporary Issues

09:00 to 10:30

Central square 2 (C2)

Oral presentation session

The Spanish Network on Research on Primary Attention on Addiction (RIAPAd): a new multilevel integrated model of responsible research on Addiction Disorders

09:00 to 10:30

Knowledge market 4 (K4)

Structured session

10:50

How can we improve global coverage of interventions to reduce drug-related harms?

10:50 to 12:20

Main stage

Structured session

New frontiers of harm reduction in drug policy

10:50 to 12:20

Networking zone 2 (N2)

e-poster guided tour

15:00

Drug deaths: A social, structural and systems analysis

15:00 to 16:30

Knowledge market 1 (K1)

Structured session

Implementing Methamphetamine Prevention Strategies into Action (IMPRESA)

15:00 to 16:30

Knowledge market 4 (K4)

Structured session

16:50

New frontiers to regulating cannabis for public health and social justice

16:50 to 18:20

Insights zone 2 (I2)

Oral presentation session

Friday, 25 November

10:50

Gender differences and gender identities in drug use, addiction and interventions: why gender matters

10:50 to 12:20

Networking zone 3 (N3)

Structured session

Portuguese Drug Policy Model. Achievements and challenges

10:50 to 12:20

Central square 2 (C2)

Structured session

13:20

Barriers in the implementation of harm reduction interventions in European prisons. From evidence to practice

13:20 to 14:50

Main stage

Structured session

Challenging issues for drug research

13:20 to 14:50

Central square 1 (C1)

Oral presentation session

15:00

The Richard Hartnoll memorial lecture

15:00 to 15:30

Main stage

Plenary session

15:30

Closing keynote: Providing care in a time of war — perspectives from Ukraine

15:30 to 16:00

Main stage

Plenary session

Presentations

Wednesday, 23 November

10:50

Oral presentation

2. Substance Use Among Populations Displaced by Conflict: Assessments, Findings, Recommendations

5. Addressing substance use and related problems in reception settings in Europe

10:50 to 12:20

Insights zone 4 (I4)

Charlotte De Kock, Klaudia Palczak

Oral presentation

6. Caregiving packages in conflict and humanitarian settings for prevention of substance use and other health and social consequences and for child protection and development

7. Understanding and Responding to Substance Use and Abuse in the Palestinian Refugee Camps inLebanon Prior to and During COVID-19 Times

10:50 to 12:20

Insights zone 4 (I4)

Marie Claire Van Hout

Oral presentation

3. Handbook on Addressing Substance Use Disorders in Humanitarian Settings – Access to Services for Displaced Populations and Host Communities in Acute and Protracted Emergencies

1. Priorities for addressing substance use disorder in humanitarian settings

Embracing public health approaches to gambling? A review of global legislative and regulatory trends

Attitudes towards alcohol policy in Europe; results of the alcohol survey in 33 European countries

New problems, new approaches: Actions for the case of non-substance addictions for adolescents and young adults

Psychological reactance and adolescent cannabis use: the role of parental warmth and monitoring

1. Annual incidence of substance-induced psychoses in Scandinavia from 2000 to 2016

10:50 to 12:20

Knowledge market 2 (K2)

Eline Borger Rognli

Oral presentation

2. Characteristics of incident substance-induced psychosis compared to incident first episode psychosis. A nationwide register-linkage study

10:50 to 12:20

Knowledge market 2 (K2)

Pihla Sassi

Oral presentation

3. Relapse rate of substance-induced psychosis and associated risk factors. A nationwide registerlinkage study

10:50 to 12:20

Knowledge market 2 (K2)

Heidi Taipale

Oral presentation

4. Substance-induced psychosis and later schizophrenia or bipolar disorder: transition rates and the role of infections

10:50 to 12:20

Knowledge market 2 (K2)

Jørgen G. Bramness

Oral presentation

5. Antipsychotic use and associating factors among persons with substance-induced psychosis and first-episode psychosis. A nationwide register-linkage study

10:50 to 12:20

Knowledge market 2 (K2)

Jeyaniroshan Jeyapalan

Oral presentation

Substance Use and Substance Use Disorders in relation to COVID-19: Qualitative Experience of Users in Jordan

10:50 to 12:20

Central square 3 (C3)

Mayyada Wazaify

Oral presentation

Overdose deaths and the COVID-19 pandemic in British Columbia, Canada

10:50 to 12:20

Central square 3 (C3)

Alexis Crabtree

Oral presentation

Changes in social work practice and support for people who use drugs during the Covid-19 pandemic – a case study of Malmö, Sweden

10:50 to 12:20

Central square 3 (C3)

Torkel Richert

Oral presentation

Drug use and attitudes toward COVID-19 vaccination in a representative sample of undergraduate students

10:50 to 12:20

Central square 3 (C3)

Stelios Stylianou

Oral presentation

Using Opioids During the COVID-19 Pandemic: experiences of people who use opioids and their healthcare providers in Nova Scotia, Canada

10:50 to 12:20

Central square 3 (C3)

Emilie Comeau

13:20

Discussion

The UNODC International Standards on Drug Use Prevention-Development of Prevention Systems

2. International Credentialling

1. Prevention Science and the Professionalization of Prevention Practice

3. Training the Prevention Workforce-Future Prevention Workforce

1. Developing a functional taxonomy for Digital Health Interventions in Addiction Services

13:20 to 14:50

Central square 2 (C2)

Joseph Tay Wee Teck

Oral presentation

3. Immersive Virtual Reality in the Assessment and Treatment of Addictive Disorders: Current Status and Future Perspectives

13:20 to 14:50

Central square 2 (C2)

Simon Langener

Oral presentation

4. Routine outcome monitoring and personalized clinical feedback for people in treatment for substance use disorders. A mixed-method adaptation study

13:20 to 14:50

Central square 2 (C2)

Øyvind Kyrre Grindheim

Discussion

Are Digital Health Interventions for Addiction Services more likely to widen or narrow inequalities?

13:20 to 14:50

Central square 2 (C2)

Marica Ferri

Oral presentation

2. Spanish version of CANreduce. Preliminary findings of a self-guided treatment program to reduce cannabis consumption

13:20 to 14:50

Central square 2 (C2)

Joan-Ignasi Mestre-Pintó

Oral presentation

1. Drug laws indicators through the leximetric approach and relationship with effectiveness: the example of Italy in the period 1991-2018

13:20 to 14:50

Knowledge market 4 (K4)

Carla Rossi

Oral presentation

2. Hospitalization risk profile of opioids users

13:20 to 14:50

Knowledge market 4 (K4)

Giada Minelli

Oral presentation

3. Using Supply Indicators in the Evaluation of Drug Supply Reduction – Challenges and Opportunities

13:20 to 14:50

Knowledge market 4 (K4)

Nicola Singleton

Oral presentation

4. Estimating the size of the of illicit drug market – a critical review

13:20 to 14:50

Knowledge market 4 (K4)

Robin Udrisard

Oral presentation

5. Estimating the costs of the criminal justice system

13:20 to 14:50

Knowledge market 4 (K4)

Francesco Fabi

Discussion

Integrating indicators and estimates

13:20 to 14:50

Knowledge market 4 (K4)

Peter H. Reuter

Oral presentation

2. Digital Health Interventions: Petiscos from clinical practice

13:20 to 14:50

Central square 2 (C2)

Roya Vaziri

15:00

Oral presentation

Fear of inpatient opioid withdrawal: Addressing a modifiable barrier to health-care access for people who use illicit opioids.

15:00 to 16:30

Knowledge market 3 (K3)

Magdalena Harris

Oral presentation

Analysis of drugs in used syringes from sentinel European cities, 2020

15:00 to 16:30

Knowledge market 3 (K3)

Thomas Seyler

Oral presentation

The impact of opioid agonist treatment on hospitalisations for injecting-related diseases: a retrospective data linkage study

15:00 to 16:30

Knowledge market 3 (K3)

Samantha Colledge-Frisby

Oral presentation

5. International cooperation to address global public health harms caused by novel psychoactive substances while protecting access to medicines

15:00 to 16:30

Central square 2 (C2)

Dilkushi Poovendran

Oral presentation

1. Early warning on emerging drug threats at the international level – opportunities and challenges

15:00 to 16:30

Central square 2 (C2)

Martin Raithelhuber

Oral presentation

2. Global markets, glocal threats: Early warning, preparedness, and response to new psychoactive substances in Europe

15:00 to 16:30

Central square 2 (C2)

Michael Evans-Brown

Oral presentation

3. Early Warning Systems are Critical to Drug Control Strategies to Protect Public Health and Safety

15:00 to 16:30

Central square 2 (C2)

Luli R. Akinfiresoye, Terrence L. Boos

Oral presentation

4. NPS Discovery: An Open Access Early Warning System for the United States

15:00 to 16:30

Central square 2 (C2)

Barry K. Logan

Oral presentation

Utilising data linkage to describe and explore mortality among a retrospective cohort of individuals admitted to residential substance use treatment.

15:00 to 16:30

Central square 3 (C3)

Tisdale Calvert

Oral presentation

It is logically not possible to quantify the number of indirect deaths

15:00 to 16:30

Central square 3 (C3)

Alfred Uhl

Oral presentation

Mortality and Morbidity in Patients in Opioid Maintenance Treatment

15:00 to 16:30

Central square 3 (C3)

Roman Gabrhelík

Oral presentation

Trends in mortality from alcohol, opioid, and combined alcohol and opioid poisonings by sex, educational attainment and race and ethnicity for the United States 2000-2018.

15:00 to 16:30

Central square 3 (C3)

Charlotte Buckley

Oral presentation

Mortality consequences of misuse of psychoactive prescription drugs in Portugal - the MisuMedPT project

15:00 to 16:30

Central square 3 (C3)

Ana Araújo

Discussion

Discussion: synergies and challenges each region faces in relation to the model/s within which DCRs operate

1. Twenty-one years of operation at the Uniting Sydney Medically Supervised Injecting Centre (MSIC) Australia

2. The rapid expansion of DCRs/SIFs in Canada in the context of a public health emergency

3. Denmark: A successful case study in community advocacy culminating in several sanctioned SIFs

15:00 to 16:30

Insights zone 3 (I3)

Michael Lodberg Olsen

Oral presentation

4. How to run an unsanctioned overdose prevention van; experiences from Glasgow 2020-2021

Anabolic androgenic steroid use population size estimation: a first stage study utilising a Delphi exercise

15:00 to 16:30

Knowledge market 4 (K4)

Vivian Hope

Oral presentation

Prevalence and socio-demographics correlates of cannabis vaping: Results from the 2018 & 2019 International Cannabis Policy Study

15:00 to 16:30

Knowledge market 4 (K4)

Gary Chan

Oral presentation

Systematic review and meta-analysis of the prevalence of prescription opioid dependence in patients with chronic non cancer pain (CNCP) treated with opioid painkillers

15:00 to 16:30

Knowledge market 4 (K4)

Kyla Thomas

Oral presentation

Prevalence and factors associated with hospitalisation for bacterial skin infections among people who inject drugs: the ETHOS Engage Study

15:00 to 16:30

Knowledge market 4 (K4)

Jason Grebely

Oral presentation

How does risk prevention (not) work? Learning from the realist, pragmatic, cluster-randomised trial of the RISKIT-CJS programme (with a null result)

15:00 to 16:30

Knowledge market 4 (K4)

Nadine Hendrie

Oral presentation

Association of opioid agonist treatment with mortality or rehospitalization following injection drug use-associated bacterial and fungal infections: linkage cohort study

15:00 to 16:30

Knowledge market 3 (K3)

Thomas Brothers

16:50

Oral presentation

1. The Impact of Economic Recessions on the Use of Illicit Drugs: a Systematic Review of Literature and a Meta-Analysis

16:50 to 18:20

Central square 4 (C4)

Claudia Costa Storti

Oral presentation

2. The impact of economic recessions on the harms of drug use and health responses, in Europe: a panel data analysis

16:50 to 18:20

Central square 4 (C4)

Bruno Casal

Oral presentation

3. Structural vulnerabilities and deaths of despair in Scotland, 1980-2021

16:50 to 18:20

Central square 4 (C4)

Mirjam Allik

Oral presentation

4. Economic conditions and opioids: An overview

16:50 to 18:20

Central square 4 (C4)

Sotiris Vandoros

Discussion

What lessons have we learn from past that apply to the COVID-19 induced recession? A structured debate

16:50 to 18:20

Central square 4 (C4)

Liesbeth Vandam

Short communication

Comparison of intranasal and intramuscular naloxone in opioid overdoses managed by ambulance staff: a double dummy, randomised, controlled trial

16:50 to 18:20

Networking zone 4 (N4)

Arne Skulberg

Oral presentation

Peer and Nursing-led Outreach Combined with Point-of-care HCV Testing to Decentralise HCV Care and Enhance HCV Treatment Among People Who Use Drugs: The REACH_U Project

16:50 to 18:20

Networking zone 4 (N4)

Cristiana Merendeiro

Short communication

Monitoring overall mortality among people who are using drugs in Europe: A good practice example for international cooperation via the REITOX network

16:50 to 18:20

Networking zone 4 (N4)

Tanja Schwarz

Short communication

Developing an Intervention to Manage Benzodiazepine Dependence and High-Risk Use in the Context of Escalating Drug Related Deaths: A feasibility study

16:50 to 18:20

Networking zone 4 (N4)

Catriona Matheson

Short communication

Housing-based syringe services programs to improve access to safe injecting supplies for people who inject drugs in Vancouver, Canada: A spatially-oriented qualitative study

16:50 to 18:20

Networking zone 4 (N4)

Koharu Loulou Chayama

Short communication

Peer involvement and intersectoral cooperation experiences in outreach work with people who use psychoactive substances: a scoping review

16:50 to 18:20

Networking zone 4 (N4)

João Pedro Ramos

Short communication

Registration for opioid agonist treatment in Ireland from 1999 to 2019: positive findings in younger individuals.

16:50 to 18:20

Networking zone 4 (N4)

Peter McCarron

Short communication

The role of a medically supervised injecting room in improving access to health and social services.

16:50 to 18:20

Networking zone 4 (N4)

Nico Clark

Oral presentation

1. International Guidelines on Human Rights and Drug Policy: From standard setting to assessing compliance

16:50 to 18:20

Knowledge market 1 (K1)

Damon Barrett

Oral presentation

2. Pompidou Group for Human rights and drug policies in Europe: A self-assessment tool

16:50 to 18:20

Knowledge market 1 (K1)

Thomas Kattau

Oral presentation

The Global Drug Policy Index

16:50 to 18:20

Knowledge market 1 (K1)

Marie Nougier

Oral presentation

3. The Global Drug Policy Index: A unique accountability tool to assess and rank countries’ drug policies

16:50 to 18:20

Knowledge market 1 (K1)

Juan Fernandez Ochoa

Oral presentation

1. The standard THC unit

2. Paving the Way for Improved Data Collection on Cannabis Use

3. The International Cannabis Toolkit (iCannToolkit): a first necessary step to integrate global multidisciplinary evidence on cannabis related risks and benefits

4. From standard drinks to the cannabis toolkit

Findings from treatment facility survey (EFSQ) in Lebanon’

16:50 to 18:20

Networking zone 2 (N2)

Zeinab Abbas

Oral presentation

European facility survey questioner (EFSQ) for Palestinian substance use disorder (SUD) treatment facilities.

16:50 to 18:20

Networking zone 2 (N2)

Saed Bilbeisi

Oral presentation

European treatment facility survey in Georgia

16:50 to 18:20

Networking zone 2 (N2)

Irakli Natsvlishvili

Oral presentation

Drug treatment facilities survey, Tunisia 2020

16:50 to 18:20

Networking zone 2 (N2)

Hajer Aounallah-Skhiri

Short communication

Barriers and facilitators for use of oral healthcare services among people with substance use disorders: A qualitative study in Norway

16:50 to 18:20

Networking zone 4 (N4)

Siv-Elin Carlsen

18:30

Discussion

Debating psychedelic-assisted treatment for substance use disorders – long overlooked or now overhyped?

18:30 to 19:30

Main stage

Tomáš Páleníček, Andrea Jungaberle, John Marsden, Gabriella Gobbi

Thursday, 24 November

09:00

Oral presentation

2. New challenges in drug monitoring: wastewater analysis as an alternative indicators for rapid epidemiological assessment of drug use trend

09:00 to 10:30

Knowledge market 4 (K4)

José Benito Quintana

Oral presentation

3. Promotion of health regarding the problematic drug use through interventions in educational and primary addiction treatment settings

09:00 to 10:30

Knowledge market 4 (K4)

Victor Villanueva

Oral presentation

4. Translational research as a necessary actor for fighting addiction: RIAPAd as a coordinated national cooperative framework

09:00 to 10:30

Knowledge market 4 (K4)

Fernando Rodriguez De Fonseca

Discussion

What is next on Addiction Research? A responsible innovative approach to societal changes in Addiction

09:00 to 10:30

Knowledge market 4 (K4)

Marta Torrens, Fernando Rodriguez De Fonseca

Oral presentation

1. Implementing patient-reported experiences (PROMs and PREMs) to improve the engagement of patients in treatment services

09:00 to 10:30

Knowledge market 4 (K4)

Joan-Ignasi Mestre-Pintó

Oral presentation

Stakeholders’ perceptions about their position and the dynamics between the stakeholders within Swedish drug policy field

09:00 to 10:30

Central square 2 (C2)

Tuulia Lerkkanen

Oral presentation

Switching from a criminalisation to a public health approach to injecting drug use in Eastern Europe and Central Asia: a modelling analysis of the costs and impact on HIV transmission

09:00 to 10:30

Central square 2 (C2)

Zoe Ward

Oral presentation

Addressing intimate partner abuse (IPA) perpetrated by heterosexual men in substance use treatment: the ADVANCE programme

09:00 to 10:30

Central square 2 (C2)

Gail Gilchrist

Oral presentation

ROSE: A peer-led intervention to support peer workers in overdose response settings in British Columbia

09:00 to 10:30

Central square 2 (C2)

Fred Cameron

10:50

e-poster

Lessons for Public Health and Public Safety from Fentanyl-Related Substances Scheduling in the United States

10:50 to 12:20

Networking zone 2 (N2)

M.J. Menendez

e-poster

20 years of decriminalisation

10:50 to 12:20

Networking zone 2 (N2)

Américo Gegaloto

e-poster

Why Social Science should matter for a pragmatic drug policy: Critical analysis of the drug policy debate in India, 1947-2020.

10:50 to 12:20

Networking zone 2 (N2)

Kawal Deep Kour

e-poster

Alcohol industry’s arguments disseminated in the mainstream press against pregnancy alcohol warning labels in France

10:50 to 12:20

Networking zone 2 (N2)

Ana Millot

e-poster

Sin tax in Poland – an example of effectiveness of fiscal measures in alcohol policy

10:50 to 12:20

Networking zone 2 (N2)

Dagmara Lebiecka

e-poster

Myths of drug consumption decriminalization: long-term effects of Portuguese decriminalization on drug-related deaths

10:50 to 12:20

Networking zone 2 (N2)

Lucas Marín-Llanes

e-poster

The association of cannabis marketing exposure with positive cannabis attitudes and cannabis use in the most permissive medical cannabis market in the U.S.

10:50 to 12:20

Networking zone 2 (N2)

Amy Cohn

e-poster

Building harm reduction focused cannabis public education materials: An example of knowledge translation with previously stigmatized communities.

10:50 to 12:20

Networking zone 2 (N2)

Daniel Bear

Oral presentation

1. Global epidemiology of injecting drug use, HIV/HCV among people who inject drugs, and coverage of interventions to reduce drug-related harms

2. Successful models for implementation of harm reduction programmes

3. How can we improve data and mobilise funding for harm reduction support globally?

4. Community advocacy and community-led monitoring to improve coverage and quality of services to reduce drug-related harms

15:00

1. Drug-related deaths among young people: a social, structural and systems autopsy

15:00 to 16:30

Knowledge market 1 (K1)

Aileen O'Gorman

Oral presentation

2. Drug-related deaths in prisons in England and Wales, 2015-2020: an examination of key trends and issues for policy and practice

15:00 to 16:30

Knowledge market 1 (K1)

Karen Duke

Oral presentation

3. The role of Primary Care in the prevention of drug-related deaths: Patient and family member perspectives

15:00 to 16:30

Knowledge market 1 (K1)

Katie Colliver

Discussion

What can a social, structural and systems analysis tell us about drug-related deaths and what are the implications for policy and addiction science?

15:00 to 16:30

Knowledge market 1 (K1)

Anne Whittaker

Oral presentation

4. The role of Primary Care in the prevention of drug-related deaths: service provider perspectives

15:00 to 16:30

Knowledge market 1 (K1)

Betsy Thom

Oral presentation

5. Drug Policy and The Rise and Decline of Racial Stratification of Prescribing and Overdose Mortality

15:00 to 16:30

Knowledge market 1 (K1)

Brian Kelly

Oral presentation

3. Development of tailored prevention intervention packages

15:00 to 16:30

Knowledge market 4 (K4)

Magdalena Rowicka

Oral presentation

1. Aims, scope and methodology of IMPRESA

15:00 to 16:30

Knowledge market 4 (K4)

Dovilė Mačiulytė

Oral presentation

2. Results of the literature review and the Delphi expert consensus finding process on Methamphetamine Prevention Interventions

15:00 to 16:30

Knowledge market 4 (K4)

Benjamin Petruželka

Oral presentation

4. The RE-AIM framework for evaluating implementation processes and public health impact

15:00 to 16:30

Knowledge market 4 (K4)

Harald Lahusen

16:50

Oral presentation

Medical cannabis regulation: Taking the best of the North American and European models

Municipal variations in cannabis regulation regarding public consumption and retail sales in Canada

Québec's public, not-for-profit cannabis distribution regime: a comparative analysis, three years in

Regulating Cannabis for Public Health

Mitigating the risks of corporate capture in emerging legal cannabis markets

Equity in Marijuana Policies: A Comparative Study of two U.S. States using Critical Race Theory.

16:50 to 18:20

Insights zone 2 (I2)

Gaby Mohr

Friday, 25 November

10:50

Oral presentation

5. Drug use among non-binary persons in Europe: findings from a web survey

10:50 to 12:20

Networking zone 3 (N3)

Cristiana Vale Pires

Oral presentation

1. What is gender and why it is necessary to incorporate a gender perspective in the drug field? Evolution of key theoretical concepts in the area of gender and trends influencing the drug field

10:50 to 12:20

Networking zone 3 (N3)

Analia Torres

Oral presentation

2. Gender differences in drug use from a social perspective

10:50 to 12:20

Networking zone 3 (N3)

Nuria Romo

Oral presentation

3. Sex differences in drug use and drug addiction from a neuroscience perspective

10:50 to 12:20

Networking zone 3 (N3)

Anne Marije Kaag

Oral presentation

4. Using an intersectional risk environment approach to understand health and drug outcomes: Looking across social locations

10:50 to 12:20

Networking zone 3 (N3)

Alexandra B. Collins

Oral presentation

6. Implementing a gender dimension in drug policy and practice: findings from the Pompidou Group handbook for practitioners and decision makers

10:50 to 12:20

Networking zone 3 (N3)

Sarah Morton

Oral presentation

3. Harm Reduction and Public Health: The place of 'subjugated knowledges'

10:50 to 12:20

Central square 2 (C2)

Daniel Martins

Oral presentation

1. How to reduce drug-related crimes

10:50 to 12:20

Central square 2 (C2)

Jorge Quintas

Oral presentation

2. 20 years of Portuguese drug policy: developments and current challenges

10:50 to 12:20

Central square 2 (C2)

Ximene Rêgo

Oral presentation

4. Drug consumption rooms in Lisbon: lessons learned

10:50 to 12:20

Central square 2 (C2)

Adriana Curado

Oral presentation

5. A strategy for all drug uses

10:50 to 12:20

Central square 2 (C2)

Maria Carmo Carvalho

Discussion

Recent developments in the gender field: the EIGE’s perspective

10:50 to 12:20

Networking zone 3 (N3)

13:20

Oral presentation

2. Hepatitis C and HIV associated risk factors among people in prison in Latvia, Lithuania, Portugal, Spain: informing interventions to prevent communicable diseases in prison setting

3. The international guidance on harm reduction interventions in prisons

5. Harm reduction interventions and viral hepatitis elimination in prison: models of care and barriers for implementation

4. Impact, role, and prevalence of medication assisted treatment (MAT) for opioid users in European prisons

1. Provision of harm reduction interventions in European prisons: short overview of available services

Substance-related Consequences, Dependence and Substance Use Disorder: Promising new model taking clinical and statistical points of view into consideration

13:20 to 14:50

Central square 1 (C1)

Rosalie Genois

Oral presentation

Language and concepts in alcohol use disorder: how framing affects stigma and recovery

13:20 to 14:50

Central square 1 (C1)

James Morris

Oral presentation

Drinking patterns across Europe. Do beverage preferences matter?

13:20 to 14:50

Central square 1 (C1)

Janusz Sieroslawski

Oral presentation

Emerging Issues in the Management of Conflict of Interest

13:20 to 14:50

Central square 1 (C1)

Matej Košir

Oral presentation

Reproducibility and translation in addiction research

13:20 to 14:50

Central square 1 (C1)

Rainer Spanagel

Discussion

Prison health in Europe

13:20 to 14:50

Main stage

Fadi Meroueh, Filipa Alves da Costa

15:00

Keynote presentation

Early warnings and outbreaks: A sociological perspective

Richard Hartnoll – a seminal contributor to the development of the EMCDDA and drug epidemiology

15:30

Providing care in a time of war — perspectives from Ukraine

15:30 to 16:00

Main stage

Irina Pinchuk